dasatinib accordpharma
accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastiske midler - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib. ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib. newly diagnosed ph+ all in combination with chemotherapy.
dasatinib sandoz 70 mg
sandoz - københavn - dasatinib - tablett, filmdrasjert - 70 mg
dasatinib sandoz 20 mg
sandoz - københavn - dasatinib - tablett, filmdrasjert - 20 mg
dasatinib sandoz 50 mg
sandoz - københavn - dasatinib - tablett, filmdrasjert - 50 mg
levotyroksinnatrium accord 75 mikrog
accord healthcare b.v. - levotyroksinnatrium - tablett - 75 mikrog
levotyroksinnatrium accord 50 mikrog
accord healthcare b.v. - levotyroksinnatrium - tablett - 50 mikrog
levotyroksinnatrium accord 100 mikrog
accord healthcare b.v. - levotyroksinnatrium - tablett - 100 mikrog
levotyroksinnatrium accord 125 mikrog
accord healthcare b.v. - levotyroksinnatrium - tablett - 125 mikrog
levotyroksinnatrium accord 150 mikrog
accord healthcare b.v. - levotyroksinnatrium - tablett - 150 mikrog
levotyroksinnatrium accord 200 mikrog
accord healthcare b.v. - levotyroksinnatrium - tablett - 200 mikrog